Cellectis S.A. (EPA: ALCLS)

Market Cap	149.34M
Revenue (ttm)	32.32M
Net Income (ttm)	-75.74M
Shares Out	100.09M
EPS (ttm)	-0.93
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,617
Open	1.518
Previous Close	1.498
Day's Range	1.462 - 1.518
52-Week Range	1.414 - 3.158
Beta	3.23
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 5, 2025

About Cellectis

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-715 and ALLO-605 for the treatment of multiple myeloma; ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UC...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 221
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALCLS

Financial Performance

In 2023, Cellectis's revenue was $9.19 million, a decrease of -64.26% compared to the previous year's $25.72 million. Losses were -$101.06 million, -4.79% less than in 2022.

Financial numbers in USD